Home › Funds › Frazier Life Sciences Management, L.P. › VOR
Frazier Life Sciences Management, L.P. position in VOR
VOR BIOPHARMA INC COM NEW · Health Care
Frazier Life Sciences Management, L.P. reported holding 2,543,939 shares of VOR (VOR BIOPHARMA INC COM NEW) in its Q2 2026 13F filing — a position valued at US$46.8M, representing 1.02% of its reported portfolio and ranking #20 among its reported holdings. Frazier Life Sciences Management, L.P. has disclosed VOR holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Frazier Life Sciences Management, L.P.'s VOR position evolved
Frazier Life Sciences Management, L.P. first disclosed a stake in VOR in Q4 2025 at 2,543,939 shares (US$33.3M). The position peaked in Q2 2026 at 2,543,939 shares, worth US$46.8M. Across 3 filings, Frazier Life Sciences Management, L.P. held the position steady without any share-count change. The most recent filing (Q2 2026) shows 2,543,939 shares valued at US$46.8M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 2.54M | $33.27M | New |
| Q1 2026 | 2.54M | $45.38M | Hold |
| Q2 2026 | 2.54M | $46.83M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About VOR and 13F data
VOR (VOR BIOPHARMA INC COM NEW) is a Health Care company. 75 other funds we track also report a position in VOR — the largest reported positions include TCG Crossover Management, LLC (US$104.4M), FCPM III SERVICES B.V. (US$75.8M), Venrock Adviser, LLC (US$56.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding VOR
- TCG Crossover Management, LLC 5.67M sh · $104.44M · Q2 2026
- FCPM III SERVICES B.V. 4.12M sh · $75.80M · Q2 2026
- Venrock Adviser, LLC 3.04M sh · $56.00M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 2.40M sh · $44.22M · Q2 2026
- Caligan Partners LP 1.93M sh · $35.44M · Q2 2026
- Paradigm Biocapital Advisors LP 1.75M sh · $32.22M · Q2 2026
- GREAT POINT PARTNERS LLC 1.70M sh · $31.30M · Q2 2026
- NEXTBio Capital Management LP 889.16K sh · $16.37M · Q2 2026
- Nantahala Capital Management, LLC 845.00K sh · $15.56M · Q2 2026
- ADAR1 Capital Management, LLC 680.63K sh · $12.53M · Q2 2026
- Logos Global Management LP 650.00K sh · $11.97M · Q2 2026
- Rosalind Advisors, Inc. 648.60K sh · $11.94M · Q2 2026
More on Frazier Life Sciences Management, L.P.
FAQ
How long has Frazier Life Sciences Management, L.P. held VOR?
Frazier Life Sciences Management, L.P. has disclosed VOR holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Frazier Life Sciences Management, L.P.'s current position in VOR?
As of Q2 2026, Frazier Life Sciences Management, L.P. holds 2.54M shares of VOR (VOR BIOPHARMA INC COM NEW), valued at $46.83M, representing 1.02% of its reported portfolio and ranking #20.
Has Frazier Life Sciences Management, L.P. been buying or selling VOR?
In the latest 13F filing (Q2 2026), Frazier Life Sciences Management, L.P. held unchanged its position in VOR. The position peaked in Q2 2026 at 2.54M shares.
Which other funds hold VOR?
Other major institutional holders of VOR include TCG Crossover Management, LLC, FCPM III SERVICES B.V., Venrock Adviser, LLC, among 75 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.